William F. Clark, MD; A. Keith Stewart, MD; Gail A. Rock, MD; Marion Sternbach, MD; David M. Sutton, MD; Brendan J. Barrett, MD; A. Paul Heidenheim, MA; Amit X. Garg, MD; David N. Churchill, MD; the Canadian Apheresis Group
ClinicalTrials.gov identifier: NCT00120263.
Grant Support: By the Canadian Institute of Health Research, Gambro BCT, and The Kidney Foundation of Canada.
Potential Financial Conflicts of Interest: Grants received: W.F. Clark (Kidney Foundation of Canada, Canadian Institute of Health Research, Gambro BCT).
Requests for Single Reprints: William F. Clark, MD, London Health Sciences Centre, 800 Commissioners Road East, London, Ontario N6A 4G5, Canada.
Current Author Addresses: Drs. Clark and Garg and Mr. Heidenheim: London Health Sciences Centre, 800 Commissioners Road East, London, Ontario N6A 4G5, Canada.
Dr. Stewart: Princess Margaret Hospital, 620 University Avenue, Toronto, Ontario M5G 2C1, Canada.
Dr. Rock: The Ottawa Hospital, 1053 Carling Avenue, Ottawa, Ontario K1Y 4E9, Canada.
Drs. Sternbach and Churchill: McMaster University, St. Joseph's Hospital, 50 Charlton East, Hamilton, Ontario L8N 1A6, Canada.
Dr. Sutton: Toronto General Hospital, 200 Elizabeth Street, Toronto, Ontario M5C 2G4, Canada.
Dr. Barrett: Memorial University of Newfoundland, 300 Prince Philip Drive, St. Johns, Newfoundland A1B 3V6, Canada.
Author Contributions: Conception and design: W.F. Clark, A.K. Stewart, G.A. Rock, M. Sternbach, B.J. Barrett, A.P. Heidenheim, D.N. Churchill.
Analysis and interpretation of the data: W.F. Clark, A.K. Stewart, B.J. Barrett, A.P. Heidenheim, A.X. Garg, D.N. Churchill.
Drafting of the article: W.F. Clark, A.K. Stewart, A.P. Heidenheim, D.N. Churchill.
Critical revision of the article for important intellectual content: W.F. Clark, A.K. Stewart, M. Sternbach, D.M. Sutton, B.J. Barrett, A.P. Heidenheim, A.X. Garg, D.N. Churchill.
Final approval of the article: W.F. Clark, A.K. Stewart, A.X. Garg, D.N. Churchill.
Provision of study materials or patients: W.F. Clark, G.A. Rock, M. Sternbach, D.M. Sutton, D.N. Churchill.
Statistical expertise: W.F. Clark, A.P. Heidenheim, A.X. Garg, D.N. Churchill.
Obtaining of funding: W.F. Clark, A.K. Stewart, D.N. Churchill.
Administrative, technical, or logistic support: W.F. Clark, G.A. Rock.
Collection and assembly of data: W.F. Clark, A.P. Heidenheim, D.N. Churchill.
Clark WF, Stewart AK, Rock GA, Sternbach M, Sutton DM, Barrett BJ, et al. Plasma Exchange When Myeloma Presents as Acute Renal Failure: A Randomized, Controlled Trial. Ann Intern Med. 2005;143:777-784. doi: 10.7326/0003-4819-143-11-200512060-00005
Download citation file:
Published: Ann Intern Med. 2005;143(11):777-784.
Does plasma exchange benefit patients with multiple myeloma and renal failure?
This 6-month randomized trial involved 104 patients with acute renal failure at the onset of myeloma. A composite outcome of death, dialysis dependence, or severely reduced kidney function occurred in 57.9% of patients given 5 to 7 plasma exchanges and in 69.2% of patients given conventional therapy (difference, 11.3% [95% CI, −8.3% to 29.1%]).
Although these findings suggest no substantial benefits of plasma exchange, the wide 95% CI around the difference between groups means that large benefit or some harm is possible.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Hematology/Oncology, Nephrology, Acute Kidney Injury, Multiple Myeloma.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only